Next Article in Journal
Adjuvant Biophysical Therapies in Osteosarcoma
Previous Article in Journal
Novel Molecular Characterization of Colorectal Primary Tumors Based on miRNAs
Article Menu

Export Article

Open AccessArticle
Cancers 2019, 11(3), 347; https://doi.org/10.3390/cancers11030347

AP001056.1, A Prognosis-Related Enhancer RNA in Squamous Cell Carcinoma of the Head and Neck

1
Department of Medical Biosciences/Pathology, Umeå University, 90185 Umeå, Sweden
2
RECAMO, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
3
Équipe Labellisée Ligue Contre le Cancer, INSERM UMRS1162, Institut de Génétique Moléculaire, Université Paris 7, IUH Hôpital St. Louis, 75010 Paris, France
4
Department of Clinical Sciences/ENT, Umeå University, 90185 Umeå, Sweden
*
Author to whom correspondence should be addressed.
Received: 11 February 2019 / Revised: 1 March 2019 / Accepted: 7 March 2019 / Published: 11 March 2019
Full-Text   |   PDF [1171 KB, uploaded 11 March 2019]   |  
  |   Review Reports

Abstract

A growing number of long non-coding RNAs (lncRNAs) have been linked to squamous cell carcinoma of the head and neck (SCCHN). A subclass of lncRNAs, termed enhancer RNAs (eRNAs), are derived from enhancer regions and could contribute to enhancer function. In this study, we developed an integrated data analysis approach to identify key eRNAs in SCCHN. Tissue-specific enhancer-derived RNAs and their regulated genes previously predicted using the computational pipeline PreSTIGE, were considered as putative eRNA-target pairs. The interactive web servers, TANRIC (the Atlas of Noncoding RNAs in Cancer) and cBioPortal, were used to explore the RNA levels and clinical data from the Cancer Genome Atlas (TCGA) project. Requiring that key eRNAs should show significant associations with overall survival (Kaplan–Meier log-rank test, p < 0.05) and the predicted target (correlation coefficient r > 0.4, p < 0.001), we identified five key eRNA candidates. The most significant survival-associated eRNA was AP001056.1 with ICOSLG encoding an immune checkpoint protein as its regulated target. Another 1640 genes also showed significant correlation with AP001056.1 (r > 0.4, p < 0.001), with the “immune system process” being the most significantly enriched biological process (adjusted p < 0.001). Our results suggest that AP001056.1 is a key immune-related eRNA in SCCHN with a positive impact on clinical outcome. View Full-Text
Keywords: AP001056.1; lncRNA; enhancer; SCCHN; ICOSLG; tumor immunity AP001056.1; lncRNA; enhancer; SCCHN; ICOSLG; tumor immunity
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Gu, X.; Wang, L.; Boldrup, L.; Coates, P.J.; Fahraeus, R.; Sgaramella, N.; Wilms, T.; Nylander, K. AP001056.1, A Prognosis-Related Enhancer RNA in Squamous Cell Carcinoma of the Head and Neck. Cancers 2019, 11, 347.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top